CPG: Immunotherapy for Inhalant Allergy

Clinical Practice Guideline: Immunotherapy for Inhalant Allergy

The purpose of this clinical practice guideline (CPG) is to identify quality improvement opportunities and provide clinicians trustworthy, evidence-based recommendations regarding the management of inhaled allergies with immunotherapy. Specific goals of the guideline are to optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce the risk of harm. The target patients for the guideline are any individuals aged 5 years and older with allergic rhinitis, with or without allergic asthma, who are either candidates for immunotherapy or treated with immunotherapy for their inhalant allergies. The target audience is all clinicians involved in the administration of immunotherapy.

Leadership

Richard K. Gurgel, MD, MSCI (Chair); Fuad M. Baroody, MD (Assistant Chair); Cecelia C. Damask, DO (Assistant Chair); James “Whit” Mims, MD (Assistant Chair); Stacey L. Ishman, MD, MPH (Methodologist)

Guideline Development Group

Dole P. Baker, Jr., MD; Kevin J. Contrera, MD, MPH; Fariha S. Farid, DO; John A. Fornadley, MD; Donna D. Gardner, DrPH, RRT, RRT-NPS; LaKeisha R. Henry, MD; Jean Kim, MD, PhD; Joshua M. Levy, MD, MPH; Christine M. Reger, DNP, CRNP; Howard J. Ritz, DMSc, PA-C; Robert J. Stachler, MD; Tulio A. Valdez, MD, MSc; Joe Reyes, MS; and Nui Dhepyasuwan, MEd

Endorsements

This guideline is endorsed by Allergy & Asthma Network, American Academy of Otolaryngic Allergy, American Osteopathic Colleges of Otolaryngology Head and Neck Surgery, American Rhinologic Society, American Society of Pediatric Otolaryngology, Society of Otorhinolaryngology and Head-Neck Nurses, and Society of Physician Assistants in Otorhinolaryngology / Head & Neck Surgery

Resources